Pipeline – Brigatinib

Overview¹

- Brigatinib is a tyrosine kinase inhibitor with selectivity for ALK and ROS 1

Mechanism of Action¹

- Brigatinib inhibited the in vitro viability of cells expressing EML4-ALK and 17 mutant forms associated with clinical resistance to ALK inhibitors at clinically achievable concentrations (≤ 500 nM)

- Brigatinib reduced tumor burden and prolonged survival in mice implanted intracranially with an ALK-driven tumor cell line

Clinical Trials

Study Name

General Use-results Survey of Alunbrig Tablets “Non-small Cell Lung Cancer” in Japan

Study Name

Post-Marketing Surveillance (Usage Results Study) of Brigatinib in the Treatment of Adult Patients for Approved Indications in South Korea

References

1. Alunbrig^® [package insert]. Takeda Pharmaceuticals America, Inc.

Disclaimers

Efficacy and safety of these products, for the uses identified within, are currently under investigation. Regulatory approval of any of these products or uses is dependent on the completion of the study programs and review by regulatory authorities. The clinical trial information is available at www.clinicaltrials.gov *Marketed products have received approval in one or more jurisdictions.